跳至主要内容
临床试验/NCT02433847
NCT02433847Unknown4 期

Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

Seoul National University Hospital0 个研究点目标入组 20 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
20
主要终点
colonic transit time

研究概览

简要总结

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria

排除标准

  • Intolerable or hypersensitive to mosapride
  • Known Parkinson's ds
  • Cardio- or cerebrovascular disease within 3 months
  • Malignancy requiring surgery or chemotherapy or radiation within 5 years
  • History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation
  • Refractory diabetes mellitus/hypertension/thyroid diseases
  • Symptomatic heart failure, renal failure, arrhythmia

研究组 & 干预措施

mosapride

Experimental

干预措施: Mosapride (Drug)

结局指标

主要结局

colonic transit time

时间窗: 2 weeks

the change of colonic transit time after mosapride 30mg/day administration : whole colonic transit time, rt. colon / lt. colon / rectosigmoid colonic transit time

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验